6.3.1.9 Glucose-dependent insulinotropic polypeptide (GIP) receptor and glucagon-like peptide-1 (GLP-1) receptor agonists

Tirzepatide is approved for treating type 2 diabetes in line with NICE TA924. For specialist initiation with specialist defined as secondary care prescribers, GPs, Specialist DSNs, and specialist pharmacists or nurses in primary care (e.g. practice or spoke nurses) who have completed PITstop or equivalent.

Interim formulary status for the use of Tirzepatide (Mounjaro) is red for its use with NICE TA 1026 - for prescribing by specialist weight management services only. Pathways are still being developed and will be shared within NHS Kent and Medway once complete. Referrals to these services should not be made until these pathways are developed.

For Mounjaro®: for once weekly dosing, one pen (4 doses) = one month’s supply.